Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase®, the WHO Pharmacovigilance Database
Cancers · 29.03.2023 · 15 (7) · 2041
DOI: 10.3390/cancers15072041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 29.03.2023. Verfasst von Morgane Cellier und 6 weiteren Autor:innen. Beteiligte Einrichtung: Service de Pharmacologie-Toxicologie et Pharmacovigilance, Centre Hospitalo-Universitaire d'Angers, 4 rue Larrey, 49100 Angers, France. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Alongside their BCR-ABL specificity, TKIs used in chronic myeloid leukemia also target other tyrosine kinases expressed in the kidney such as PDGFR, c-KIT, SRC, and VEGFR, which may result in specific renal adverse drug reaction (ADR). To evaluate the renal safety profile in real-life conditions, a case/non-case study was performed on VigiBase®, the WHO global safety database.
Methods
From 7 November 2001 to 2 June 2021, all cases in which the involvement of imatinib, dasatinib, nilotinib, bosutinib, and ponatinib was suspected in the occurrence of renal ADR were extracted from VigiBase®. Disproportionality analyses were assessed using the reporting odds ratio.
Results
A total of 1409 cases were included. Imatinib accounts for half of the reported cases. A signal of disproportionate reporting (SDR) of renal failure and fluid retention was found for the five TKIs. Only dasatinib and nilotinib were related to an SDR for nephrotic syndrome. Nilotinib and ponatinib were related to an SDR for renal artery stenosis, while dasatinib was related to an SDR for thrombotic microangiopathy. No SDR for tubulointerstitial nephritis was observed.
Conclusion
This study identified a new safety signal, nephrotic syndrome, for nilotinib and highlights the importance of post-marketing safety surveillance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Service de Pharmacologie-Toxicologie et Pharmacovigilance, Centre Hospitalo-Universitaire d'Angers, 4 rue Larrey, 49100 Angers, France.
- Service de Néphrologie, Centre Hospitalo-Universitaire d'Angers, 4 rue Larrey, 49100 Angers, France.
- UFR Santé, Université d'Angers, 49100 Angers, France.
- Laboratoire MitoVasc, UMR CNRS 6214 INSERM 1083, 49100 Angers, France.
ORCID-Profile: Laurence Lagarce, Marie Briet
Zitieren
APA
Cellier, M., Bourneau-Martin, D., Abbara, C., Crosnier, A., Lagarce, L., Garnier, A. S., & Briet, M. (2023). Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase®, the WHO Pharmacovigilance Database. Cancers, 15(7), 2041. https://doi.org/10.3390/cancers15072041
Vancouver
Cellier M, Bourneau-Martin D, Abbara C, Crosnier A, Lagarce L, Garnier AS, et al. Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase®, the WHO Pharmacovigilance Database. Cancers. 2023;15(7):2041. doi:10.3390/cancers15072041
BibTeX
@article{Cellier2023,
author = {Cellier, Morgane and Bourneau-Martin, Delphine and Abbara, Chadi and Crosnier, Alexandre and Lagarce, Laurence and Garnier, Anne-Sophie and Briet, Marie},
title = {Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase®, the WHO Pharmacovigilance Database},
journal = {Cancers},
year = {2023},
volume = {15},
number = {7},
pages = {2041},
doi = {10.3390/cancers15072041}
}
EUVIMED